Argus reiterates Zimmer Biomet stock rating on restructuring plan By Investing.com

Argus reiterated a Buy on Zimmer Biomet with a $125 price target and notes the stock trades at 9.8x Argus’s 2027 EPS estimate (current P/E 24.85) and near a 52-week low of $84.59. The company reported Q4 results that beat expectations but issued a cautious 2026 outlook; management is restructuring the U.S. sales force which may slow 2026 sales but is expected to support stronger, sustainable growth in 2027+. BTIG downgraded ZBH to Neutral (removed a $112 target) while William Blair initiated Market Perform, reflecting mixed analyst views. Investors are pointed to attractive valuation metrics and a 15-year dividend payment streak as supportive for long-term upside.

Analysis

The announced U.S. sales-force overhaul is a classic near-term growth headwind that, if executed, should improve pricing discipline and takeout of low-productivity coverage — a two- to three-year structural margin lever rather than an immediate revenue accelerator. That timing mismatch creates a window where culture and incentive misalignment can depress execution and market share (hospitals gravitate to vendors with stable rep coverage), so watch rep churn and OR coverage metrics over the next 6–12 months as a proxy for implementation risk.

M&A-driven product breadth creates cross-sell optionality but also amplifies integration execution risk: overlapping SKUs, inventory rebalancing, and channel rationalization tend to pressure near-term gross margins for 6–18 months before synergies hit. Suppliers of implants and proprietary consumables (and third-party logistics partners) are the second-order beneficiaries if cross-sell succeeds; conversely, independent distributors and smaller OEMs face margin squeeze as consolidated vendors bundle offerings to hospitals.

Key catalysts that will re-rate the name are concrete signs of stabilized OR coverage, faster-than-expected cross-sell conversion rates, and a clear cadence of margin recovery into 2027; negative catalysts are a macro surgical-volume shock, regulatory recalls, or slower physician adoption of new SKUs. Near-term volatility is likely: earnings beats without upward guidance will probably produce muted rallies, while visible progress in 12–24 month execution metrics should trigger outsized multiple expansion relative to peers.

The consensus underappreciates the optionality embedded in a successful sales-force reconfiguration — multiple expansion is plausible if execution reduces selling costs and improves ASPs — but it also understates integration and reimbursement risk. Position sizing should therefore reflect binary outcomes: either a multi-year re-rate or a drawn-out consolidation with limited upside, so use structures that cap downside while leaving meaningful upside exposure.

Key Decisions for Investors

• Directional long with defined downside: Buy ZBH 12–18 month LEAP calls with ~0.30–0.40 delta (target 30–60% upside) funded by selling nearer-term calls (3–6 months) to finance premium. Rationale: captures 2027 re-rating if sales-force execution and cross-sell accelerate; risk: theta decay and execution misses—limit to 2–3% portfolio allocation.
• Pair trade to express relative-opportunity: Long ZBH equity (or LEAP) / Short SYK (equal dollar) for 12–24 months. Rationale: if ZBH re-rates from restructuring while larger peer already priced richly, the pair isolates execution upside; risk: broad group multiple expansion that lifts both—use 10–15% stop-loss on pair basis.
• Income-enhanced hold: Buy ZBH stock and sell 3–6 month covered calls to boost yield while providing limited upside cap. Rationale: collects premium during the restructuring transition and offsets near-term volatility; risk: forfeiting upside on strong re-rate events—keep strike above target re-rate level and size relative to dividend income goals.
• Short-term hedge around catalysts: Buy 3–6 month protective puts or put spreads on ZBH ahead of any quarterly update that could give more 2026 color. Rationale: downside protection against guidance misses or negative OR coverage metrics; cost-effective put-spread sizing at 1–2% portfolio risk for material event protection.